Sort
10,766 grants matching “checkpoint inhibitor”
LONG-ACTING PEG-LIKE CONJUGATES OF AN IMMUNE CHECKPOINT INHIBITOR AND A SELECTIVE CYTOKINE FOR COMBINATION IMMUNOTHERAPY
$127,167Duke University · · FY2020 · Department of the Army
Specialized Cancer Center Support Grant
$127,134Scott M Lippman · University Of California, San Diego · P30 · FY2021 · CA
Immune suppressor mechanisms in patients with GI cancer
$127,122Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Replication Associated Genetic Rearrangements
$126,486Susan Thomas Lovett · Brandeis University · R01 · FY2007 · GM
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma
$126,252Heather Lynn Gardner · Tufts University Boston · K01 · FY2022 · OD
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma
$126,252Heather Lynn Gardner · Tufts University Boston · K01 · FY2023 · OD
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma
$126,252Heather Lynn Gardner · Tufts University Boston · K01 · FY2021 · OD
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma
$126,252Heather Lynn Gardner · Tufts University Boston · K01 · FY2024 · OD
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma
$126,252Heather Lynn Gardner · Tufts University Boston · K01 · FY2020 · OD
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
$126,024Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2017 · CA
Evaluation of Barriers to Completion of Breast Cancer Treatment at a Tertiary Teaching and Referral Center in Kenya
$125,933Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2022 · CA
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites
$125,895Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · K08 · FY2020 · CA
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites
$125,895Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · K08 · FY2022 · CA
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites
$125,895Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · K08 · FY2023 · CA
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites
$125,895Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · K08 · FY2021 · CA
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sites
$125,895Ravi Bhasker Patel · University Of Wisconsin-Madison · K08 · FY2019 · CA
14 3 3 Implications in Topoisomerase II Pharmacology
$125,739Duke University · R01 · FY2001 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$125,695Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Mechanisms of Autoimmune Diabetes in Patients Treated with Immune checkpoint Inhibitors
$125,625Kevan C Herold · Yale University · R21 · FY2019 · AI
Mechanisms of Autoimmune Diabetes in Patients Treated with Immune checkpoint Inhibitors
$125,625Kevan C Herold · Yale University · R21 · FY2018 · AI
Core A: Administration, Integration, Education and Career Development
$125,496Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2022 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS
$125,418Mayo Clinic Coll Of Medicine, Rochester · K08 · FY2003 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS
$125,418Mayo Clinic Coll Of Medicine, Rochester · K08 · FY2002 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS
$125,418Mayo Clinic Coll Of Medicine, Rochester · K08 · FY2001 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS
$125,418Mayo Clinic Coll Of Medicine, Rochester · K08 · FY2000 · CA